Lungcancer Clinical Trial
Official title:
Imaging Multiparametric/Multimodality (Magnetic Resonance Imaging Combined With Positron Emission Tomography) for Lungcancer
1. To build an imaging biobank of 200 patients with lungcancer, including pathologic and molecular characteristics of the tumor (mutational status, circulating DeoxyriboNucleic Acid (DNA) from serum biobank…), staging of the cancer (according to the new 2016 Tumor Node Metastasis (TNM) status, the table that classify non-small cell lungcancer) and follow-up informations (Response to first-line treatment (Response Evaluation Criteria in Solid Tumors (RECIST)), disease-free survival, 1-3 years survival). 2. To propose a simple severity scoring system based on tumor features such as size, doubling time (if available), location, amount of enhancement and necrosis. Such approach has been proposed for glioma evaluation (Visually Accessible Rembrandt Images (VASARI)) but is not available for the lung. The objective is to do better than the Tumor Node Metastasis (TNM) staging. 3. To develop and evaluate an IntraVoxel Incoherent Motion (IVIM) protocol for lungcancer evaluation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
| Completed |
NCT02285426 -
HD+ I-scan Bronchoscopy Vascular Abnormalities Detection Multicenter Study
|
||
| Completed |
NCT04321499 -
SHOX2_PTGER4 DNA Methlyation in Lung Cancer
|
||
| Recruiting |
NCT03020251 -
Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer
|
N/A | |
| Completed |
NCT02962999 -
Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation
|
Phase 4 | |
| Completed |
NCT02185690 -
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
|
Phase 1 |